Skip to Main Content

Paper Details

Monovalent SARS-CoV-2 mRNA Vaccine Does not Boost Omicron-Specific Immune Response in Diabetic and Control Pediatric Patients.
J Infect Dis
0
2024
COVID-19, COVID-19 mRNA, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 mRNA, T1D, children, diabetic, mRNA, non, patients, pediatric, spike protein, spike protein-specific T cells, type 1 diabetes
Author NameAffiliation
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
  • 1 - 2

Datasets

Release 1.2